Uncertainty in the minimum event risk to justify treatment was evaluated.
OBJECTIVE
To derive expressions for the standard errors (SEs) and coefficients of variation (CV) of the threshold number needed to treat (NNT(t)) and the minimum target event risk for treatment (MERT).


METHODS
NNT(t) reflects the point at which the risks and costs of a clinical intervention balance the benefit. MERT defines the minimum target event risk at which the intervention is justified. Uncertainty in these measures has not previously been investigated.


RESULTS
SEs for NNT(t) and MERT were derived. The corresponding CVs are particularly useful, because they decompose the variability of NNT(t) and MERT into the uncertainty in their components (the values of target and adverse events, and the adverse event risk [AER]). The precision required for these components to formulate treatment recommendations is, thereby, highlighted. These ideas were illustrated with data concerning warfarin treatment for atrial fibrillation.


CONCLUSIONS
Our expressions for uncertainty in NNT(t) and MERT inform the confidence one has in initiating a clinical intervention. In our example, a recommendation for treatment could be made for groups of patients whose risk exceeded the range of uncertainty in MERT. However, for lower-risk patients, a recommendation for or against treatment could not be made, mainly because of the limited data on AERs. Our methods can also be used to estimate how much additional data would be required to provide a firmer recommendation for such patient groups.
Walter
Stephen D
SD
Department of Clinical Epidemiology and Biostatistics, McMaster University, HSC-2C16, Hamilton, Ontario, Canada. walter@mcmaster.ca
Sinclair
John C
JC
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D003627:Data Interpretation, Statistical; D003657:Decision Making; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D018570:Risk Assessment / Q000379:methods*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D035501:Uncertainty; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin